港股異動丨貝康醫療再升近5% 7月中旬至今累計升幅超35%
格隆匯7月31日丨貝康醫療-B(2170.HK)再升近5%,報3.47港元,7月中旬至今累計升幅超35%。消息面上,近日貝康醫療披露了2023年上半年業績預吿,預計上半年實現總收益約在7940萬元至8780萬元之間,同比增長15.7%至28.0%;控股子公司BMX於上半年實現總收益預計為4360萬元至4460萬元之間,同比增長19.7%至22.5%。對於業績增長的原因,貝康醫療表示,上半年得益於輔助生殖門診量恢復,企業的PGT-A試劑盒及超低温存儲設備的銷售額有所增長,同時,BMX的產品在若干亞洲國家的銷售額也取得了增加。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.